Showing 2791-2800 of 3010 results for "".
- FDA Approves Mirvaso for Treating Facial Erythema of Rosaceahttps://practicaldermatology.com/news/20130826-fda_approves_mirvaso_for_treating_facial_erythema_of_rosacea/2459476/The FDA recently approved Mirvaso (brimonidine) gel, 0.33% for the topical treatment of the facial erythema of rosacea in adults 18 years of age or older. According to manufacturer Galderma Laboratories, applied once
- Psoriasis Foundation Urges CMS to Halt Proposed Cuts to Phototherapy Reimbursementhttps://practicaldermatology.com/news/20130815-psoriasis_foundation_urges_cms_to_halt_proposed_cuts_to_phototherapy_reimbursement/2459477/The National Psoriasis Foundation has stepped up efforts to halt the Centers for Medicare and Medicaid Services (CMS) plan to cut reimbursement rates to phototherapy in the proposed CY 2014 Medicare Physician Fee Schedule (PFS). According to the Foundation, if the proposed cuts pass, many physicians
- AARS Hosting Acne and Rosacea Bootcamp September 6-8, 2013https://practicaldermatology.com/news/20130809-aars_hosting_acne_and_rosacea_bootcamp_september_6-8_2013/2459481/The American Acne and Rosacea Society (AARS) is hosting the Acne and Rosacea Bootcamp, a two-day CME event open to all medical health professionals involved in the management of acne and rosacea. The program will be held September 6-8, 2013 at the Hyatt Chicago Magnificent Mile. This event will p
- Merz North America Appoints New Chief Financial Officerhttps://practicaldermatology.com/news/20130807-merz_north_america_appoints_new_chief_financial_officer/2459482/Merz North America has appointed John Donofrio as Chief Financial Officer and Head of Business Development - North America. In this role, Donofrio will be primarily accountable for financial performance, cost management, and strategic business planning and analysis for the Finance organization in No
- Merz Acquires Neocutis' Skin Care Divisionhttps://practicaldermatology.com/news/20130801-merz_acquires_neocutis/2459486/Merz Pharma Group has acquired the cosmetics, over-the-counter, and prescription skin care businesses of Swiss dermatology company Neocutis. The company's North American division will integrate marketing of Neocutis' line of physician-dispensed topical skin care products in the US. “Neocutis' line
- Congress Establishes New Caucus on Skin Cancerhttps://practicaldermatology.com/news/20130708-congress_establishes_new_caucus_on_skin_cancer/2459502/A new bipartisan Congressional Member Organization will address the growing epidemic of skin cancer among Americans. Led by representatives Jim Cooper (D-TN-5th), Carolyn Maloney (D-NY-12th), Peter Roskam (R-IL-6th), and Charlie Dent (R-PA-15th), the caucus will support legislative activities and pr
- Merz North America Appoints New Vice Presidenthttps://practicaldermatology.com/news/20130702-merz_north_america_appoints_new_vice_president/2459503/Greg Besase has been appointed Vice President of Merz North America. Besase joined Merz in December 2012 as Director of Marketing, Dermatology and has served as the interim head of the U.S. Dermatology Business Unit since February 2013.
- Phase III Data Show Galderma's Topical Redness Reducer is Effective, Safehttps://practicaldermatology.com/news/20130625-phase_iii_data_show_galdermas_topical_redness_reducer_is_effective_safe/2459511/Topical brimonidine tartrate gel 0.5% is safe and effective for the management of erythema of rosacea, with benefit evidence as early as 30 minutes after application, new data show. (JDD, 12(6):650-656) Data from two identically designed randomized, double-blind, vehicle controlled phase III trials
- Geneticists Research Cleft Palate and Skin Deformitieshttps://practicaldermatology.com/news/20130614-geneticists_research_cleft_palate_and_skin_deformities/2459514/Scientists at Cold Spring Harbor Laboratory (CSHL) solved the mystery of why some infants are born with cleft palate and major deformities of the skin and limbs, while other infants with the same genetic mutation bear little or no sign of the illness, called Ectodactyly, Ectodermal dysplasia, Clefti
- Renaissance and GlaxoSmithKline Transfer Nine Productshttps://practicaldermatology.com/news/20130605-renaissance_and_glaxosmithkline_transfer_nine_products/2459522/Renaissance Acquisition Holdings, LLC and GlaxoSmithKline entered into an agreement giving Renaissance the rights in the USA to manufacture, market, and sell six dermatology and three anti-viral products from GSK. The products from GSK and Stiefel, which will be marketed through Renaissance's bran